Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Decreased by Jennison Associates LLC

Jennison Associates LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 63.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,393,554 shares of the biopharmaceutical company’s stock after selling 2,375,382 shares during the period. Jennison Associates LLC owned about 0.07% of Bristol-Myers Squibb worth $71,503,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. OFI Invest Asset Management purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth approximately $25,000. Milestone Investment Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 200 shares in the last quarter. Legacy Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth approximately $39,000. Finally, VisionPoint Advisory Group LLC boosted its holdings in shares of Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BMY. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Trading Up 0.4 %

NYSE:BMY opened at $49.14 on Tuesday. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93. The firm has a market cap of $99.59 billion, a price-to-earnings ratio of 12.73, a P/E/G ratio of 1.48 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The company’s 50 day moving average is $51.22 and its 200-day moving average is $51.38.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same quarter last year, the firm posted $1.82 earnings per share. The company’s quarterly revenue was up .6% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.88%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.